Nate Kelley was mentioned in multiple publications regarding the U.S. Court of Appeals for the Federal Circuit's ruling to uphold the U.S. Patent Trial and Appeal Board decision to invalidate a patent on Johnson & Johnson's prostate cancer drug, Zytiga.

"It’s a big win for former PTO Solicitor Nate Kelley, who now practices at the firm and who argued the appeal on behalf of some nine different generic defendants." (Law.com*)

05.14.2019 - Law360* - "Fed. Circ. Backs PTAB Ax of J&J Prostate Cancer Drug Patent"

05.14.2019 - Law.com* - "Skilled in the Art: Pharma Patents: The Good, the Bad and the Vaguely Familiar + FTC Cracks on DOJ"

*Subscription-based publication